Interrogating open issues in cancer precision medicine with patient-derived xenografts
Nature Reviews Cancer 17, 254 (2017).
doi:10.1038/nrc.2016.140
Authors: Annette T. Byrne, Denis G. Alférez, Frédéric Amant, Daniela Annibali, Joaquín Arribas, Andrew V. Biankin, Alejandra Bruna, Eva Budinská, Carlos Caldas, David K. Chang, Robert B. Clarke, Hans Clevers, George Coukos, Virginie Dangles-Marie, S. Gail Eckhardt, Eva Gonzalez-Suarez, Els Hermans, Manuel Hidalgo, Monika A. Jarzabek, Steven de Jong, Jos Jonkers, Kristel Kemper, Luisa Lanfrancone, Gunhild Mari Mælandsmo, Elisabetta Marangoni, Jean-Christophe Marine, Enzo Medico, Jens Henrik Norum, Héctor G. Palmer, Daniel S. Peeper, Pier Giuseppe Pelicci, Alejandro Piris-Gimenez, Sergio Roman-Roman, Oscar M. Rueda, Joan Seoane, Violeta Serra, Laura Soucek, Dominique Vanhecke, Alberto Villanueva, Emilie Vinolo, Andrea Bertotti & Livio Trusolino
Patient-derived xenografts (PDXs) have emerged as an important platform to elucidate new treatments and biomarkers in oncology. PDX models are used to address clinically relevant questions, including the contribution of tumour heterogeneity to therapeutic responsiveness, the patterns of cancer evolutionary dynamics during tumour progression and
Source: Nature Reviews Cancer - Category: Cancer & Oncology Authors: Annette T. Byrne Denis G. Alf érez Fr édéric Amant Daniela Annibali Joaqu ín Arribas Andrew V. Biankin Alejandra Bruna Eva Budinsk á Carlos Caldas David K. Chang Robert B. Clarke Hans Clevers George Coukos Virginie Dangles-Marie S. Gail Eckhardt Eva Tags: Perspectives Source Type: research
More News: Cancer | Cancer & Oncology